Coronado Biosciences

One under-$10 biopharmaceutical player that's quickly moving within range of triggering a major breakout trade is Coronado Biosciences (CNDO), which is focused on novel immunotherapy biologic agents for autoimmune diseases and cancer. This stock has been hit hard by the bears in 2013, with shares off by 43%.

>>5 Stocks Poised for Breakouts

If you take a look at the chart for Coronado Biosciences, youll notice that this stock has been uptrending strong since it double bottomed in November, with shares moving higher from its low of $1.25 to its intraday high of $2.58 a share. During that uptrend, shares of CNDO have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of CNDO within range of triggering a major breakout trade.

Traders should now look for long-biased trades in CNDO if it manages to break out above some key overhead resistance at $2.70 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.97 million shares. If that breakout hits soon, then CNDO will set up to re-fill some of its previous gap down zone from October that started near $7 a share. Some possible upside targets if CNDO gets into that gap with volume are $4 to $5 a share.

Traders can look to buy CNDO off any weakness to anticipate that breakout and simply use a stop that sits right around some key near-term support at $2 a share. One can also buy CNDO off strength once it takes out $2.70 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

If you liked this article you might like

Analysts' Actions -- Baker Hughes, ConocoPhillips, GameStop, Toll Brothers and More

Insider Trading Alert - NCMI, GGP And ARTX Traded By Insiders

Insider Trading Alert - CRM, ARTX And APOL Traded By Insiders

Trade-Ideas: Arotech (ARTX) Is Today's Strong On High Relative Volume Stock

Arotech (ARTX) Stock Gains Today on Earnings Beat